

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of:)	
CHO et al.)	Art Unit: 1646
)	
Serial No. 10/587,371)	Examining Attorney: Not Assigned
)	
Filed: July 26, 2006)	Confirmation No.: 1687
)	
Title: MODIFIED HUMAN)	
FOUR HELICAL)	
BUNDLE)	
POLYPEPTIDES AND)	
THEIR USES)	

San Diego, California
February 1, 2008

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir or Madam:


Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence, and anything referred to as enclosed herein, is being transmitted to the United States Patent and Trademark Office via the Office electronic filing system in accordance with 37 CFR §1.6(a)(4) on the 1st day of February, 2008.

By:


Amy M. Sheridan

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 50-3417 the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee and that it is accompanied by both:

- ☐ Statement in Accordance with §1.97(e) (attached); and
- ☐ Please charge Deposit Account No. 50-3417 the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached substitute for Form 1449/PTO are enclosed herewith EXCEPT THAT:

☐ Copies of each U.S. patent application publication and U.S. patent are not included since the IDS is filed in an application filed after June 30, 2003 or entered the national stage under 35 USC 371 after June 30, 2003 pursuant to 37 CFR § 1.98(a)(2)(i).

☐ Copies of references listed on the attached substitute for Form 1449/PTO are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of written English-language translations of those listed non-English language references, or portions thereof, namely, English-language abstracts, pursuant to 37 CFR 1.98(3)(ii).

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.


Atty Docket No. AMBX-0028.00US

Serial No. 10/587,371

Page 4

Please charge any deficiency or credit any overpayment to Deposit Account No. 503417.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "John W. Wallen, III", is written over a horizontal line. The signature is fluid and cursive.

John W. Wallen, III, Esq.

Reg. No. 35,403

Attorney for Applicants

AMBRX, Inc.

10975 North Torrey Pines Road, Suite 100

La Jolla, California 92037

(858) 875-2403

DATE: January 30, 2008